medigraphic.com
ISSN 2007-4360 (Print)
Asociación Mexicana de Periodontología, Colegio de Periodoncistas A.C

2018, Number 1-2

<< Back Next >>

Rev Mex Periodontol 2018; 9 (1-2)

Macrophage migration inhibitor factor in periodontal disease

Ortiz-García YM, García-Iglesias T, Hernández-Hernández A, Morales VG, Cervantes-Cabrera JJ, Zamora-Pérez AL

Language: Spanish
References: 32
Page: 14-19
PDF size: 333.68 Kb.


ABSTRACT

The term periodontal disease encompasses a wide variety of chronic inflammatory conditions of the periodontium, including gingivitis and periodontitis. Periodontitis is an infectious disease, which occurs due to the progression of untreated gingivitis. It is characterized by a destructive inflammatory process that affects the supporting tissues of the teeth, which causes the loss the teeth. Numerous inflammatory cytokines and mediators contribute to tissue degradation and bone resorption. In the inflammatory process of this disease, there are molecules little studied as a macrophage migration inhibiting factor that is considered an important cytokine of the innate immune system; is expressed constitutively in immune cells and not immune; is released immediately in response to stimuli bacterial, hypoxia and proliferative signals. Previous research has shown that macrophage migration inhibiting factor can participate in the pathophysiology of chronic degenerative and autoimmune diseases; also other studies have shown that macrophage migration inhibiting factor is an enhancer of osteoclastogenesis in periodontitis model in mice. Due to functional characteristics, macrophage migration inhibiting factor may be involved in the immunopathology of periodontal disease.


REFERENCES

  1. Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015; 15 (1): 30-44.

  2. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. Nat Rev Dis Primers. 2017; 3: 17038.

  3. Kinane DF, Lappin DF. Immune processes in periodontal disease: a review. Ann Periodontol. 2002; 7 (1): 62-71.

  4. Sochalska M, Potempa J. Manipulation of neutrophils by Porphyromonas gingivalis in the development of periodontitis. Front Cell Infect Microbiol. 2017; 7: 197.

  5. Xiong X, Buekens P, Fraser WD, Beck J, Offenbacher S. Periodontal disease and adverse pregnancy outcomes: a systematic review. BJOG. 2006; 113 (2): 135-143.

  6. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary of current work. Lab Invest. 1976; 34 (3): 235-249.

  7. Yucel-Lindberg T, Båge T. Inflammatory mediators in the pathogenesis of Periodontitis. Expert Rev Mol Med. 2013; 15: e7.

  8. Song B, Zhang YL, Chen LJ, Zhou T, Huang WK, Zhou X et al. The role of Toll-like receptors in periodontitis. Oral Dis. 2017; 23 (2): 168-180.

  9. Hajishengallis G. Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response. Trends Immunol. 2014; 35 (1): 3-11.

  10. Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol. 2011; 38 (Suppl. 11): 60-84.

  11. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003; 3 (10): 791-800.

  12. Nobre CC, de Araújo JM, Fernandes TA, Cobucci RN, Lanza DC, Andrade VS et al. Macrophage migration inhibitory factor (MIF): biological activities and relation with cancer. Pathol Oncol Res. 2017; (2): 235-244.

  13. Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 2010; 23 (4): 257-264.

  14. Lolis E, Bucala R. Macrophage migration inhibitory factor. Expert Opin Ther Targets. 2003; 7 (2): 153-164.

  15. Rosado JD, Rodríguez SM. Macrophage migration inhibitory factor (MIF): a key player in protozoan infections. Int J Biol Sci. 2011; 7 (9): 1239-1256.

  16. Mawhinney L, Armstrong ME, O’Reilly C, Bucala R, Leng L, Fingerle-Rowson G et al. Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. Mol Med. 2015; 20: 729-735.

  17. Galvão I, Dias AC, Tavares LD, Rodrigues IP, Queiroz-Junior CM, Costa VV et al. Macrophage migration inhibitory factor drives neutrophil accumulation by facilitating IL-1β production in a murine model of acute gout. J Leukoc Biol. 2016; 99 (6): 1035-1043.

  18. Tillmann S, Bernhagen J, Noels H. Arrest functions of the MIF ligand/ receptor axes in atherogenesis. Front Immunol. 2013; 4: 115.

  19. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007; 13 (5): 587-596.

  20. Morimoto T, Nishihira J, Kohgo T. Immunohistochemical localization of macrophage migration inhibitory factor (MIF) in human gingival tissue and its pathophysiological functions. Histochem Cell Biol. 2003; 120 (4): 293-298.

  21. Li X, Lan HY, Huang XR, Zhang C, Jin LJ. Expression profile of macrophage migration-inhibitory factor in human gingiva and reconstituted human gingival epithelia stimulated by Porphyromonas gingivalis lipopolysaccharide. J Periodontal Res. 2013; 48 (4): 527-532.

  22. Nonnenmacher C, Helms K, Bacher M, Nüsing RM, Susin C, Mutters R et al. Effect of age on gingival crevicular fluid concentrations of MIF and PGE2. J Dent Res. 2009; 88 (7): 639-643.

  23. Gürkan A, Eren G, Çetinkalp Ş, Akçay YD, Emingil G, Atilla G. Monocyte chemotactic protein-1, RANTES and macrophage migration inhibitory factor levels in gingival crevicular fluid of metabolic syndrome patients with gingivitis. Arch Oral Biol. 2016; 69: 82-88.

  24. De Souza MB, Curioni OA, Kanda JL, De Carvalho MB. Serum and salivary macrophage migration inhibitory factor in patients with orals quamous cell carcinoma. Oncol Lett. 2014; 8 (5): 2267-2275.

  25. Edwards KM, Bosch JA, Engeland CG, Cacioppo JT, Marucha PT. Elevated macrophage migration inhibitory factor (MIF) is associated with depressive symptoms, blunted cortisol reactivity to acute stress, and lowered morning cortisol. Brain Behav Immun. 2010; 24 (7): 1202-1208.

  26. Lundh D, Hedelin H, Jonsson K, Gifford M, Larsson D. Assessing chronic pelvic pain syndrome patients: blood plasma factors and cortisol saliva. Scand J Urol. 2013; 47 (6): 521-528.

  27. Lira-Junior R, Öztürk VÖ, Emingil G, Bostanci N, Boström EA. Salivary and serum markers related to innate immunity in generalized aggressive periodontitis. J Periodontol. 2017; 88 (12): 1339-1347.

  28. Madeira MF, Queiroz JC, Costa GM, Santos PC, Silveira EM, Garlet GP et al. MIF induces osteoclast differentiation and contributes to progression of periodontal disease in mice. Microbes Infect. 2012; 14 (2): 198-206.

  29. Liu L, Peng B. The expression of macrophage migration inhibitory factor is correlated with receptor activator of nuclear factor kappa B ligand in induced rat periapical lesions. J Endod. 2013; 39 (8): 984-989.

  30. Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle RG et al. Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine. 2015; 72 (2): 135-145.

  31. Kim HR, Kim KW, Jung HG, Yoon KS, Oh HJ, Cho ML et al. Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res Ther. 2011; 13 (2): R43.

  32. Movila A, Ishii T, Albassam A, Wisitrasameewong W, Howait M, Yamaguchi T et al. Macrophage migration inhibitory factor (MIF) supports homing of osteoclast precursors to peripheral osteolytic lesions. J Bone Miner Res. 2016; 31 (9): 1688-1700.




2020     |     www.medigraphic.com